quantiblue Search Results


quantiblue assay  (BioAssay Systems LLC)
90
BioAssay Systems LLC quantiblue assay
Combined effect of IL-6, IFN-γ, and MCP-1 on neuroglial (HFN and HFA) damage. ( A, B ) HFA and ( D, E ) HFN were treated with different doses of IL-6 (75 to 750 pg/ml) or IFN-γ (100 to 1,000 pg/ml) either alone or together (150 pg/ml IL-6 and 200 pg/ml IFN-γ). Toxicity was determined by LDH assay at 48 h after treatment. ( C ) IL-6 and IFN-γ, alone or in combination with MCP-1 (5 ng/ml), were tested in modulating mitochondrial membrane potential in HIV-1-treated astrocytes after 12 h of treatment. ( F ) Dose response of MCP-1 (1–25 ng/ml) in inducing neuroglial toxicity. ( G, H) , Effect of IL-6 and IFN-γ in combinations with HIV-1 on the ( G ) toxicity profile (LDH) and ( H ) viability <t>(MTT/QuantiBlue)</t> of neurons at 48 h after treatment. Effects of IL-6, IFN-γ, and MCP-1 in combination with HIV-1 in modulating ( I ) toxicity (LDH) and ( J ) viability (QuantiBlue) at 48 h post-treatment in neurons. MCP, monocyte chemotactic protein; HFN, human fetal neurons; HFA, human fetal astrocytes; LDH, lactate dehydrogenase.
Quantiblue Assay, supplied by BioAssay Systems LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantiblue assay/product/BioAssay Systems LLC
Average 90 stars, based on 1 article reviews
quantiblue assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
quantiblue colorimetric reagent  (Autogen-Bioclear ltd)
90
Autogen-Bioclear ltd quantiblue colorimetric reagent
Combined effect of IL-6, IFN-γ, and MCP-1 on neuroglial (HFN and HFA) damage. ( A, B ) HFA and ( D, E ) HFN were treated with different doses of IL-6 (75 to 750 pg/ml) or IFN-γ (100 to 1,000 pg/ml) either alone or together (150 pg/ml IL-6 and 200 pg/ml IFN-γ). Toxicity was determined by LDH assay at 48 h after treatment. ( C ) IL-6 and IFN-γ, alone or in combination with MCP-1 (5 ng/ml), were tested in modulating mitochondrial membrane potential in HIV-1-treated astrocytes after 12 h of treatment. ( F ) Dose response of MCP-1 (1–25 ng/ml) in inducing neuroglial toxicity. ( G, H) , Effect of IL-6 and IFN-γ in combinations with HIV-1 on the ( G ) toxicity profile (LDH) and ( H ) viability <t>(MTT/QuantiBlue)</t> of neurons at 48 h after treatment. Effects of IL-6, IFN-γ, and MCP-1 in combination with HIV-1 in modulating ( I ) toxicity (LDH) and ( J ) viability (QuantiBlue) at 48 h post-treatment in neurons. MCP, monocyte chemotactic protein; HFN, human fetal neurons; HFA, human fetal astrocytes; LDH, lactate dehydrogenase.
Quantiblue Colorimetric Reagent, supplied by Autogen-Bioclear ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantiblue colorimetric reagent/product/Autogen-Bioclear ltd
Average 90 stars, based on 1 article reviews
quantiblue colorimetric reagent - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
quantiblue  (Tecan Systems)
90
Tecan Systems quantiblue
Combined effect of IL-6, IFN-γ, and MCP-1 on neuroglial (HFN and HFA) damage. ( A, B ) HFA and ( D, E ) HFN were treated with different doses of IL-6 (75 to 750 pg/ml) or IFN-γ (100 to 1,000 pg/ml) either alone or together (150 pg/ml IL-6 and 200 pg/ml IFN-γ). Toxicity was determined by LDH assay at 48 h after treatment. ( C ) IL-6 and IFN-γ, alone or in combination with MCP-1 (5 ng/ml), were tested in modulating mitochondrial membrane potential in HIV-1-treated astrocytes after 12 h of treatment. ( F ) Dose response of MCP-1 (1–25 ng/ml) in inducing neuroglial toxicity. ( G, H) , Effect of IL-6 and IFN-γ in combinations with HIV-1 on the ( G ) toxicity profile (LDH) and ( H ) viability <t>(MTT/QuantiBlue)</t> of neurons at 48 h after treatment. Effects of IL-6, IFN-γ, and MCP-1 in combination with HIV-1 in modulating ( I ) toxicity (LDH) and ( J ) viability (QuantiBlue) at 48 h post-treatment in neurons. MCP, monocyte chemotactic protein; HFN, human fetal neurons; HFA, human fetal astrocytes; LDH, lactate dehydrogenase.
Quantiblue, supplied by Tecan Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantiblue/product/Tecan Systems
Average 90 stars, based on 1 article reviews
quantiblue - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Combined effect of IL-6, IFN-γ, and MCP-1 on neuroglial (HFN and HFA) damage. ( A, B ) HFA and ( D, E ) HFN were treated with different doses of IL-6 (75 to 750 pg/ml) or IFN-γ (100 to 1,000 pg/ml) either alone or together (150 pg/ml IL-6 and 200 pg/ml IFN-γ). Toxicity was determined by LDH assay at 48 h after treatment. ( C ) IL-6 and IFN-γ, alone or in combination with MCP-1 (5 ng/ml), were tested in modulating mitochondrial membrane potential in HIV-1-treated astrocytes after 12 h of treatment. ( F ) Dose response of MCP-1 (1–25 ng/ml) in inducing neuroglial toxicity. ( G, H) , Effect of IL-6 and IFN-γ in combinations with HIV-1 on the ( G ) toxicity profile (LDH) and ( H ) viability (MTT/QuantiBlue) of neurons at 48 h after treatment. Effects of IL-6, IFN-γ, and MCP-1 in combination with HIV-1 in modulating ( I ) toxicity (LDH) and ( J ) viability (QuantiBlue) at 48 h post-treatment in neurons. MCP, monocyte chemotactic protein; HFN, human fetal neurons; HFA, human fetal astrocytes; LDH, lactate dehydrogenase.

Journal: Journal of Neuroinflammation

Article Title: Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator

doi: 10.1186/1742-2094-9-239

Figure Lengend Snippet: Combined effect of IL-6, IFN-γ, and MCP-1 on neuroglial (HFN and HFA) damage. ( A, B ) HFA and ( D, E ) HFN were treated with different doses of IL-6 (75 to 750 pg/ml) or IFN-γ (100 to 1,000 pg/ml) either alone or together (150 pg/ml IL-6 and 200 pg/ml IFN-γ). Toxicity was determined by LDH assay at 48 h after treatment. ( C ) IL-6 and IFN-γ, alone or in combination with MCP-1 (5 ng/ml), were tested in modulating mitochondrial membrane potential in HIV-1-treated astrocytes after 12 h of treatment. ( F ) Dose response of MCP-1 (1–25 ng/ml) in inducing neuroglial toxicity. ( G, H) , Effect of IL-6 and IFN-γ in combinations with HIV-1 on the ( G ) toxicity profile (LDH) and ( H ) viability (MTT/QuantiBlue) of neurons at 48 h after treatment. Effects of IL-6, IFN-γ, and MCP-1 in combination with HIV-1 in modulating ( I ) toxicity (LDH) and ( J ) viability (QuantiBlue) at 48 h post-treatment in neurons. MCP, monocyte chemotactic protein; HFN, human fetal neurons; HFA, human fetal astrocytes; LDH, lactate dehydrogenase.

Article Snippet: Results were expressed as percent LDH release calculated as follows: % LDH = OD test / OD total × 100 Cell viability was quantified using QuantiBlue assay (Bioassay Systems) [ ], which uses a redox nonfluorescent dye, resuzurin; this is reduced to a highly fluorescent product by metabolically active cells.

Techniques: Lactate Dehydrogenase Assay, Membrane